Advancements In Endometrial Cancer: Targeted Therapies And Immunotherapies
Received Date: Aug 01, 2025 / Published Date: Aug 29, 2025
Abstract
Endometrial cancer treatment is advancing with targeted therapies and immunotherapies addressing resistance. Key strategies involve targeting PI3K, HER2, and DNA mismatch repair deficiencies. Pembrolizumab demonstrates efficacy in MSI-H/dMMR populations. Precision medicine and genomic profiling guide personalized treatment selection. Combination therapies and novel agents targeting resistance mechanisms are critical for improving outcomes. Liquid biopsies offer non-invasive monitoring and personalized therapeutic guidance. Ongoing research focuses on identifying new molecular targets for future drug development.
Citation: Lee DB (2025) Advancements In Endometrial Cancer: Targeted Therapies And Immunotherapies. Current Trends Gynecol Oncol 10: 287
Copyright: © 2025 Dr. Benjamin Lee This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 185
- [From(publication date): 0-0 - Apr 05, 2026]
- Breakdown by view type
- HTML page views: 136
- PDF downloads: 49
